Partners
Partners

Partner 32 - Menarini Silicon Biosystems


Dr. Barbara Baggiani

 

EFPIA Deputy Coordinator

 

Phone: +39 (051) 4071 300

undefinedE-Mail

 

 

Menarini Silicon Biosystems

 

Via dei Lapidari, 12

40129 Bologna

Italy

 

undefinedWebsite

CANCER-ID Team Menarini Silicon Biosystems

Dr. Nicoló Manaresi

 

Principal Investigator and CSO

 

Phone: +0514071300

undefinedE-Mail

 

 

 

Dr. Francesca Fontana

 

Biology R&D Manager/ Molecular Analysis

 

Phone: +0514071300

undefinedE-Mail

 

Dr. Genny Buson

 

Biologist/Molecular Analysis

 

Phone: +0514071300

undefinedE-Mail

 

 

Dr. Paola Tononi

 

Biologist/Molecular Analysis

 

Phone: +0514071300

undefinedE-Mail

Dr. Claudio Forcato

 

Biologist/Molecular Analysis

 

Phone: +0514071300

undefinedE-Mail

 

 

Dr. Mario Terracciano

 

Biologist/Whole Genome Analysis and CTC isolation

 

Phone: +0514071300

undefinedE-Mail

Dr. Giulia Bregola

 

Biologist/Whole Genome Analysis and CTC isolation

 

Phone: +0514071300

undefinedE-Mail

 

 

Dr. Gianni Medoro

 

CTO

 

Phone: +0514071300

undefinedE-Mail

Dr. Stefano Gianni

 

Software Project Leader

 

Phone: +0514071300

undefinedE-Mail

 

 

Dr. Giulio Signorini

 

Software Designer

 

Phone: +0514071300

undefinedE-Mail

Company presentation

Silicon Biosystems (a company of the Menarini Group) is an ISO 13485 certified medical device manufacturer and has experience in product development and commercialization, as well as CE-IVD, specifically in CTCs.
The company has developed the DEPArray™ image-based sorting technology with single-cell resolution for rare-cells, and commercializes the Ampli1™ WGA which is considered the best-in-class product to amplify DNA from single-cells.
With its pioneering work and experience in CTC molecular characterization, MSB will contribute to the overall design of the assessment process for CTC technologies toward Clinical Utility.
MSB will also contribute to the definition of goals and specifications, design of experiment for methods and technologies characterization, and by directly participating to the experimental plan for single-cell isolation and characterization methods.
Ampli1™ WGA, the whole genome amplification method commercialized by MSB can be used to generate micrograms of DNA from a single cell. Even more,  Ampli1™ WGA products can be re-amplified with negligible loss in sample quality yielding -from a single-cell- a virtually unlimited amount of material for current and future analysis needs. Silicon Biosystems will work with IBBL to define strategies and policies to implement methods and SOPs for banking of CTC-derived nucleic acids, which may be made available to consortium partners as appropriate.
The staff involved will be mainly from the Biology R&D group, and will be involved in both direct work related to the work packages and support to the consortium partners for the deployment and integration of the company technologies for cell isolation and molecular characterization at selected partners sites to carry out the clinical trials of the project.

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

developed by TATAA Biocenter and the Institute of Biotechnology, BIOCEV. Read more

Social Media

LinkedIn Cancer-ID